For recurrent pterygium, wait at least 6 months before re-operation. Use the surgical technique described for primary pterygium with the modification that the pterygium body removal should start at the limbal region. Carefully detach the head and body of the pterygium from the cornea and perilimbal bulbar sclera (to create bare sclera).
The first aim is to recess (but not resect) the entire fibrovascular tissue to the fornix (in a tension-free state). The second aim is to seal the gap between the conjunctiva and the Tenon using 9-0 Nylon running sutures. Intraoperative application of MMC is not mandatory. AMT can be performed as well.
Dr. Tseng, received his MD from National Taiwan University Medical School in 1978, and his PhD from University of California San Francisco in 1981. He completed the ophthalmology residency at Johns Hopkins Hospital in 1984 and the cornea and external disease fellowship at Massachusetts Eye & Ear Infirmary, Harvard Medical School, in 1986. He then was as a Charlotte Breyer Rodgers chair professor at Bascom Palmer Eye Institute University of Miami School of Medicine until 2002, when he resigned to assume the position as medical director of the Ocular Surface Center and the Ocular Surface Research & Education Foundation. He served as the first President of International Ocular Surface Society from 2000 to 2004, ad hoc members of NIH study sections from 2002, and the editorial board of Ocular Surface Journal and Cornea Journal. He has given several named lecture such as Ulrich Ollendorff Lecture (1999), Marvin Henry MD Memorial Lecture (2003), Kersley Lecture (2004), Oliver H. Dabezies Jr. M.D. Lecture (2005), James E. McDonald, M.D. Keynote Lecture (2005), Susrata Lecture (2006), and 60 th Japanese Clinical Ophthalmology Congress Keynote Lecture (2006), and received several honors and awards such as Chancellor Award (2002), Senior Achievement Award (2004, and Secretariat Award (2005) from American Academy of Ophthalmology. Dr. Tseng is specialized in ocular surface diseases and reconstruction using new surgical techniques of epithelial stem cell transplantation and amniotic membrane transplantation. He is also the R & D Director, leading a research team of 12 people in Bio-tissue/TissueTech, the leading tissue engineering company in Ophthalmology in the USA.
